Gary B. Willars
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gary B. Willars has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Graeme F. Wilkinson
2 shared publicationsJing Lu
Department of Molecular and Cell Biology, University of Leicester, University Road, Leicester LE1 9HN, U.K.
2 shared publications- Robert Alfred John Challiss
University of Leicester
2 shared publications Yan Huang
Department of Cell Physiology and Pharmacology, University of Leicester, Leicester, UK
2 shared publicationsAndrew B Tobin
Department of Cell Physiology and Pharmacology, University of Leicester, Leicester, UK
1 shared publicationAndrew B. Tobin
1 shared publication
Latest Publications
- 8 February 2019
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 476 (3) , 513-533
Endothelin-converting enzyme-1 regulates glucagon-like peptide-1 receptor signalling and resensitisation
Following nutrient ingestion, glucagon-like peptide 1 (GLP-1) is secreted from intestinal L-cells and mediates anti-diabetic effects, most notably stimulating glucose-dependent insulin release from pancreatic β-cells but also inhibiting glucagon release, promoting satiety and weight reduction and potentially enhancing or preserving β-cell mass. These effects are mediated by the GLP-1 receptor (GLP-1R), which is a therapeutic target in type 2 diabetes. Although agonism at the GLP-1R has been well studied, desensitisation and resensitisation are perhaps less well explored. An understanding of these events is important, particularly in the design and use of novel receptor ligands. Here, using either HEK293 cells expressing the recombinant human GLP-1R or the pancreatic β-cell line, INS-1E with endogenous expressesion of the GLP-1R, we demonstrate GLP-1R desensitisation and subsequent resensitisation following removal of extracellular GLP-1 7-36 amide. Resensitisation is dependent on receptor internalisation, endosomal acidification and receptor recycling. Resensitisation is also regulated by endothelin-converting enzyme-1 (ECE-1) activity, most likely through proteolysis of GLP-1 in endosomes and the facilitation of GLP-1R dephosphorylation and recycling. Inhibition of ECE-1 activity also increases GLP-1-induced activation of extracellular signal-regulated kinase and generation of cAMP, suggesting processes dependent upon the lifetime of the internalised ligand–receptor complex.
- 8 February 2019
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 476 (3) , 513-533
Endothelin-converting enzyme-1 regulates glucagon-like peptide-1 receptor signalling and resensitisation
Following nutrient ingestion, glucagon-like peptide 1 (GLP-1) is secreted from intestinal L-cells and mediates anti-diabetic effects, most notably stimulating glucose-dependent insulin release from pancreatic β-cells but also inhibiting glucagon release, promoting satiety and weight reduction and potentially enhancing or preserving β-cell mass. These effects are mediated by the GLP-1 receptor (GLP-1R), which is a therapeutic target in type 2 diabetes. Although agonism at the GLP-1R has been well studied, desensitisation and resensitisation are perhaps less well explored. An understanding of these events is important, particularly in the design and use of novel receptor ligands. Here, using either HEK293 cells expressing the recombinant human GLP-1R or the pancreatic β-cell line, INS-1E with endogenous expressesion of the GLP-1R, we demonstrate GLP-1R desensitisation and subsequent resensitisation following removal of extracellular GLP-1 7-36 amide. Resensitisation is dependent on receptor internalisation, endosomal acidification and receptor recycling. Resensitisation is also regulated by endothelin-converting enzyme-1 (ECE-1) activity, most likely through proteolysis of GLP-1 in endosomes and the facilitation of GLP-1R dephosphorylation and recycling. Inhibition of ECE-1 activity also increases GLP-1-induced activation of extracellular signal-regulated kinase and generation of cAMP, suggesting processes dependent upon the lifetime of the internalised ligand–receptor complex.
- 1 July 2018
- Published by Elsevier in Molecular Pharmacology
- Vol. 94 (1) , 674-688
Ligand-Specific Signaling Profiles and Resensitization Mechanisms of the Neuromedin U2 Receptor
The structurally related, but distinct neuropeptides, neuromedin U (NmU) and neuromedin S (NmS) are ligands of two G protein-coupled NmU receptors (NMU1, NMU2). Hypothalamic NMU2 regulates feeding behavior and energy expenditure and has therapeutic potential as an anti-obesity target, making an understanding of its signaling and regulation of particular interest. NMU2 binds both NmU and NmS with high affinity, resulting in receptor-ligand co-internalization. We have investigated whether receptor trafficking events post-internalization are 9biased9 by the ligand bound and can therefore influence signaling function. Using recombinant cell-lines expressing human NMU2, we demonstrate that acute Ca2+ signaling responses to NmU or NmS are indistinguishable and that restoration of responsiveness (resensitization) requires receptor internalization and endosomal acidification. The rate of NMU2 resensitization is faster following NmU compared to NmS exposure, but is similar if endothelin-converting enzyme-1 activity is inhibited or knocked-down. Although acute activation of extracellular signal-regulated kinase (ERK) is also similar, activation by NMU2 is longer-lasting if NmS is the ligand. Furthermore, when cells were briefly challenged before removal of free, but not receptor-bound ligand, activation of ERK and p38 mitogen-activated protein kinase by NmS is more sustained, but only NmU responses are potentiated and extended by ECE-1 inhibition. These data indicate that differential intracellular ligand processing produces different signaling and receptor resensitization profiles and add to the findings of other studies demonstrating that intracellular ligand processing can shape receptor behavior and signal transduction.
- 1 July 2018
- Published by Elsevier in Molecular Pharmacology
- Vol. 94 (1) , 674-688
Ligand-Specific Signaling Profiles and Resensitization Mechanisms of the Neuromedin U2 Receptor
The structurally related, but distinct neuropeptides, neuromedin U (NmU) and neuromedin S (NmS) are ligands of two G protein-coupled NmU receptors (NMU1, NMU2). Hypothalamic NMU2 regulates feeding behavior and energy expenditure and has therapeutic potential as an anti-obesity target, making an understanding of its signaling and regulation of particular interest. NMU2 binds both NmU and NmS with high affinity, resulting in receptor-ligand co-internalization. We have investigated whether receptor trafficking events post-internalization are 9biased9 by the ligand bound and can therefore influence signaling function. Using recombinant cell-lines expressing human NMU2, we demonstrate that acute Ca2+ signaling responses to NmU or NmS are indistinguishable and that restoration of responsiveness (resensitization) requires receptor internalization and endosomal acidification. The rate of NMU2 resensitization is faster following NmU compared to NmS exposure, but is similar if endothelin-converting enzyme-1 activity is inhibited or knocked-down. Although acute activation of extracellular signal-regulated kinase (ERK) is also similar, activation by NMU2 is longer-lasting if NmS is the ligand. Furthermore, when cells were briefly challenged before removal of free, but not receptor-bound ligand, activation of ERK and p38 mitogen-activated protein kinase by NmS is more sustained, but only NmU responses are potentiated and extended by ECE-1 inhibition. These data indicate that differential intracellular ligand processing produces different signaling and receptor resensitization profiles and add to the findings of other studies demonstrating that intracellular ligand processing can shape receptor behavior and signal transduction.
- 12 June 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (13) , 3194-3195
British Pharmacological Society, 5th Focused Meeting on Cell Signalling: Matters arising …
Linked Articles: This article is part of a themed section on 5th BPS Focused Meeting on Cell Signalling. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue‐13
- 12 June 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (13) , 3194-3195
British Pharmacological Society, 5th Focused Meeting on Cell Signalling: Matters arising …
Linked Articles: This article is part of a themed section on 5th BPS Focused Meeting on Cell Signalling. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue‐13
- Open Access
- 19 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47936
Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
Glucagon-like peptide-1 (GLP-1) released from intestinal L cells in response to nutrients has many physiological effects but particularly enhances glucose-dependent insulin release through the GLP-1 receptor (GLP-1R). GLP-1 7–36 amide, the predominant circulating active form of GLP-1, is rapidly truncated by dipeptidyl peptidase-4 to GLP-1 9–36 amide, which is generally considered inactive. Given its physiological roles, the GLP-1R is targeted for treatment of type 2 diabetes. Recently ‘compound 2’ has been described as both an agonist and positive allosteric modulator of GLP-1 7–36 amide affinity, but not potency, at the GLP-1R. Importantly, we demonstrated previously that exendin 9–39, generally considered a GLP-1R antagonist, enhances compound 2 efficacy (or vice versa) at the GLP-1R. Given that GLP-1 9–36 amide is the major circulating form of GLP-1 post-prandially and is a low affinity weak partial agonist or antagonist at the GLP-1R, we investigated interaction between this metabolite and compound 2 in a cell line with recombinant expression of the human GLP-1R and the rat insulinoma cell line, INS-1E, with native expression of the GLP-1R. We show compound 2 markedly enhances efficacy and potency of GLP-1 9–36 amide for key cellular responses including AMP generation, Ca2+ signaling and extracellular signal-regulated kinase. Thus, metabolites of peptide hormones including GLP-1 that are often considered inactive may provide a means of manipulating key aspects of receptor function and a novel therapeutic strategy.
- 19 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47936
Open AccessAllosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
Glucagon-like peptide-1 (GLP-1) released from intestinal L cells in response to nutrients has many physiological effects but particularly enhances glucose-dependent insulin release through the GLP-1 receptor (GLP-1R). GLP-1 7–36 amide, the predominant circulating active form of GLP-1, is rapidly truncated by dipeptidyl peptidase-4 to GLP-1 9–36 amide, which is generally considered inactive. Given its physiological roles, the GLP-1R is targeted for treatment of type 2 diabetes. Recently ‘compound 2’ has been described as both an agonist and positive allosteric modulator of GLP-1 7–36 amide affinity, but not potency, at the GLP-1R. Importantly, we demonstrated previously that exendin 9–39, generally considered a GLP-1R antagonist, enhances compound 2 efficacy (or vice versa) at the GLP-1R. Given that GLP-1 9–36 amide is the major circulating form of GLP-1 post-prandially and is a low affinity weak partial agonist or antagonist at the GLP-1R, we investigated interaction between this metabolite and compound 2 in a cell line with recombinant expression of the human GLP-1R and the rat insulinoma cell line, INS-1E, with native expression of the GLP-1R. We show compound 2 markedly enhances efficacy and potency of GLP-1 9–36 amide for key cellular responses including AMP generation, Ca2+ signaling and extracellular signal-regulated kinase. Thus, metabolites of peptide hormones including GLP-1 that are often considered inactive may provide a means of manipulating key aspects of receptor function and a novel therapeutic strategy.
- 5 May 2011
- Published by Springer Nature
- Vol. 746, 53-84
Generation of Epitope-Tagged GPCRs
The addition of one or more epitope tags to G-protein-coupled receptors (GPCRs) has facilitated a wide variety of studies on their structure and function. Epitope-tagging is achieved using relatively straightforward molecular techniques but requires careful consideration about the nature of the epitope tag and its location within the receptor. Here, we describe both the strategies and methodologies for the generation of epitope-tagged GPCRs. We highlight a range of possible techniques that depend upon the available starting material, the nature of the epitope to be incorporated, and suggest a strategy to ease the tagging of multiple receptor types.
- 5 May 2011
- Published by Springer Nature
- Vol. 746, 53-84
Generation of Epitope-Tagged GPCRs
The addition of one or more epitope tags to G-protein-coupled receptors (GPCRs) has facilitated a wide variety of studies on their structure and function. Epitope-tagging is achieved using relatively straightforward molecular techniques but requires careful consideration about the nature of the epitope tag and its location within the receptor. Here, we describe both the strategies and methodologies for the generation of epitope-tagged GPCRs. We highlight a range of possible techniques that depend upon the available starting material, the nature of the epitope to be incorporated, and suggest a strategy to ease the tagging of multiple receptor types.
- 1 September 2010
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 334 (3) , 795-808
Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent “Compound 2” at the GLP-1 Receptor
Glucagon-like peptide-1 (GLP-1) mediates antidiabetogenic effects through the GLP-1 receptor (GLP-1R), which is targeted for the treatment of type 2 diabetes. Small-molecule GLP-1R agonists have been sought due to difficulties with peptide therapeutics. Recently, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (compound 2) has been described as a GLP-1R allosteric modulator and agonist. Using human embryonic kidney-293 cells expressing human GLP-1Rs, we extended this work to consider the impact of compound 2 on G protein activation, Ca2+ signaling and receptor internalization and particularly to compare compound 2 and GLP-1 across a range of functional assays in intact cells. GLP-1 and compound 2 activated Gαs in cell membranes and increased cellular cAMP in intact cells, with compound 2 being a partial and almost full agonist, respectively. GLP-1 increased intracellular [Ca2+] by release from intracellular stores, which was mimicked by compound 2, with slower kinetics. In either intact cells or membranes, the orthosteric antagonist exendin-(9-39), inhibited GLP-1 cAMP generation but increased the efficacy of compound 2. GLP-1 internalized enhanced green fluorescent protein-tagged GLP-1Rs, but the speed and magnitude evoked by compound 2 were less. Exendin-(9-39) inhibited internalization by GLP-1 and also surprisingly that by compound 2. Compound 2 displays GLP-1R agonism consistent with action at an allosteric site, although an orthosteric antagonist increased its efficacy on cAMP and blocked compound 2-mediated receptor internalization. Full assessment of the properties of compound 2 was potentially hampered by damaging effects that were particularly manifest in either longer term assays with intact cells or in acute assays with membranes.
- 1 September 2010
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 334 (3) , 795-808
Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent “Compound 2” at the GLP-1 Receptor
Glucagon-like peptide-1 (GLP-1) mediates antidiabetogenic effects through the GLP-1 receptor (GLP-1R), which is targeted for the treatment of type 2 diabetes. Small-molecule GLP-1R agonists have been sought due to difficulties with peptide therapeutics. Recently, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (compound 2) has been described as a GLP-1R allosteric modulator and agonist. Using human embryonic kidney-293 cells expressing human GLP-1Rs, we extended this work to consider the impact of compound 2 on G protein activation, Ca2+ signaling and receptor internalization and particularly to compare compound 2 and GLP-1 across a range of functional assays in intact cells. GLP-1 and compound 2 activated Gαs in cell membranes and increased cellular cAMP in intact cells, with compound 2 being a partial and almost full agonist, respectively. GLP-1 increased intracellular [Ca2+] by release from intracellular stores, which was mimicked by compound 2, with slower kinetics. In either intact cells or membranes, the orthosteric antagonist exendin-(9-39), inhibited GLP-1 cAMP generation but increased the efficacy of compound 2. GLP-1 internalized enhanced green fluorescent protein-tagged GLP-1Rs, but the speed and magnitude evoked by compound 2 were less. Exendin-(9-39) inhibited internalization by GLP-1 and also surprisingly that by compound 2. Compound 2 displays GLP-1R agonism consistent with action at an allosteric site, although an orthosteric antagonist increased its efficacy on cAMP and blocked compound 2-mediated receptor internalization. Full assessment of the properties of compound 2 was potentially hampered by damaging effects that were particularly manifest in either longer term assays with intact cells or in acute assays with membranes.
- 1 August 2009
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 330 (2) , 502-512
Full and Partial Agonists of Muscarinic M3 Receptors Reveal Single and Oscillatory Ca2+ Responses by β2-Adrenoceptors
Under physiological circumstances, cellular responses often reflect integration of signaling by two or more different receptors activated coincidentally or sequentially. In addition to heterologous desensitization, there are examples in which receptor activation either reveals or potentiates signaling by a different receptor type, although this is perhaps less well explored. Here, we characterize one such interaction between endogenous receptors in human embryonic kidney 293 cells in which Gαq/11-coupled muscarinic M3 receptors facilitate Ca2+ signaling by Gαs-coupled β2-adrenoceptors. Measurement of changes in intracellular [Ca2+] demonstrated that noradrenaline released Ca2+ from thapsigargin-sensitive intracellular stores only during activation of muscarinic receptors. Agonists with low efficacy for muscarinic receptor-mediated Ca2+ responses facilitated cross-talk more effectively than full agonists. The cross-talk required Gαs and was dependent upon intracellular Ca2+ release channels, particularly inositol (1,4,5)-trisphosphate receptors. However, β2-adrenoceptor-mediated Ca2+ release was independent of measurable increases in phospholipase C activity and resistant to inhibitors of protein kinases A and C. Interestingly, single-cell imaging demonstrated that particularly lower concentrations of muscarinic receptor agonists facilitated marked oscillatory Ca2+ signaling to noradrenaline. Thus, activation of muscarinic M3 receptors profoundly influences the magnitude and oscillatory behavior of intracellular Ca2+ signaling by β2-adrenoceptors. Although these receptor subtypes are often coexpressed and mediate contrasting acute physiological effects, altered oscillatory Ca2+ signaling suggests that cross-talk could influence longer term events through, for example, regulating gene transcription.
- 1 August 2009
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 330 (2) , 502-512
Full and Partial Agonists of Muscarinic M3 Receptors Reveal Single and Oscillatory Ca2+ Responses by β2-Adrenoceptors
Under physiological circumstances, cellular responses often reflect integration of signaling by two or more different receptors activated coincidentally or sequentially. In addition to heterologous desensitization, there are examples in which receptor activation either reveals or potentiates signaling by a different receptor type, although this is perhaps less well explored. Here, we characterize one such interaction between endogenous receptors in human embryonic kidney 293 cells in which Gαq/11-coupled muscarinic M3 receptors facilitate Ca2+ signaling by Gαs-coupled β2-adrenoceptors. Measurement of changes in intracellular [Ca2+] demonstrated that noradrenaline released Ca2+ from thapsigargin-sensitive intracellular stores only during activation of muscarinic receptors. Agonists with low efficacy for muscarinic receptor-mediated Ca2+ responses facilitated cross-talk more effectively than full agonists. The cross-talk required Gαs and was dependent upon intracellular Ca2+ release channels, particularly inositol (1,4,5)-trisphosphate receptors. However, β2-adrenoceptor-mediated Ca2+ release was independent of measurable increases in phospholipase C activity and resistant to inhibitors of protein kinases A and C. Interestingly, single-cell imaging demonstrated that particularly lower concentrations of muscarinic receptor agonists facilitated marked oscillatory Ca2+ signaling to noradrenaline. Thus, activation of muscarinic M3 receptors profoundly influences the magnitude and oscillatory behavior of intracellular Ca2+ signaling by β2-adrenoceptors. Although these receptor subtypes are often coexpressed and mediate contrasting acute physiological effects, altered oscillatory Ca2+ signaling suggests that cross-talk could influence longer term events through, for example, regulating gene transcription.
- 1 June 2006
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 17 (3) , 363-376
Mammalian RGS proteins: Multifunctional regulators of cellular signalling
- 1 June 2006
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 17 (3) , 363-376
Mammalian RGS proteins: Multifunctional regulators of cellular signalling